Latham Named “Life Sciences Group of the Year”

January 13, 2015
Global team’s M&A and IPO dealmaking highlighted by Law360.

Citing the firm’s leading role in initial public offerings and M&A deals for cutting-edge clients, including work on more than US$350 billion in transactions during 2014, Law360 has named the Life Sciences Industry Group of Latham & Watkins as “Life Sciences Group of the Year.” 

Latham attorneys handled “nearly a third of the IPOs in the life sciences industry since 2013, and half of the top 10 biotech company IPO deals in 2014…some of which outperformed the market” noted Law360. Beyond the team’s banner year in capital markets, Law360 spotlighted the group’s wide-ranging capabilities and experience, noting “the team worked with its life sciences clients…on every aspect of their businesses…and also handled headline mergers and acquisitions.”

“We’re large enough and have such a deep bench in terms of partners, associates and other support areas given the way that Latham is set up,” said Peter Handrinos, global co-chair of Latham’s Life Sciences team. “It’s truly group success.”

The global footprint of Latham’s Life Sciences group and the unique scientific expertise of the team were also noted by Law360.

“If my colleagues can understand the science behind a product, that becomes particularly important when doing deals,” said Alan Mendelson, global co-chair of the firm's Life Sciences Industry Group. “When biotech or device companies are looking for a lawyer, they want someone who’s been through the war, but also who has a great team with strong experience.”